.webp)
Simulates human biology with AI to predict drug effects and run virtual trials.
Company Overview
Competitors
Protein-Centric AI
Isomorphic Labs, Recursion, Insilico Medicine
Foundation Model Bio
Genentech (scGPT), Microsoft (BioGPT), Owkin
Virtual Biology
Cellarity, Relation Therapeutics
Agentic Drug Discovery
FutureHouse (Robin), Emerald Cloud Lab
CellType
's Moat:
C2S-Scale 27B model for cell biology simulation, validated by Google's CEO and experimental confirmation of a novel cancer hypothesis. Foundation model trained on proprietary single-cell datasets that pharma competitors would need years to assemble. All deals coming inbound from top-10 pharma suggests the moat is the science itself.
How They're Leveraging AI
AI Use Overview:
Using virtual biology simulation via Cell2Sentence foundation models, agentic multi-omics reasoning across 30+ biomedical APIs, and patient stratification modeling.
Ditto Biosciences
Mines parasite genomes to discover protein therapeutics for autoimmune diseases.
Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.
Mango Medical
Automates surgical planning for orthopedic procedures from CT scans using agentic AI.
Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.
Origin
Designs regulatory DNA that outperforms DeepMind for safer, more precise gene therapies.
Gene therapies need precise regulatory DNA elements to control where and when genes express. Origin's Axis model outperforms DeepMind's AlphaGenome by 6.7% on activity prediction, with free API access for researchers and pharma partnerships forming.
